Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Where Arrowhead Pharmaceuticals Stands With Analysts
09:35pm, Tuesday, 24'th May 2022 Benzinga
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
1
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
02:02pm, Wednesday, 11'th May 2022 Benzinga
Upgrades
According to Roth Capital, the prior rating for Hecla Mining Co (NYSE:HL) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from th
Arrowhead Pharmaceuticals (ARWR) Q2 2022 Earnings Call Transcript
06:00am, Wednesday, 11'th May 2022 The Motley Fool
ARWR earnings call for the period ending March 31, 2022.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q2 2022 Results - Earnings Call Transcript
09:57pm, Tuesday, 10'th May 2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
01:23pm, Thursday, 14'th Apr 2022
Yes, the MMs must have such forecasts, adjusted minute-by-minute each trading day by their upstairs desks' direct-wire connections to trading desks at billion-$ institutional portfolios. Those forecas
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
11:30am, Tuesday, 15'th Mar 2022 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
The Best Russell 2000 Stocks to Buy Before they Rebound
03:06pm, Tuesday, 15'th Feb 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
06:16am, Saturday, 12'th Feb 2022
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
Arrowhead Pharmaceuticals (ARWR) Stock: Why The Price Fell
05:47am, Friday, 04'th Feb 2022
The stock price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) fell by 6.92% in the most recent trading session. This is why it happened.
Arrowhead Pharmaceuticals (ARWR) Q1 2022 Earnings Call Transcript
02:30am, Friday, 04'th Feb 2022 The Motley Fool
ARWR earnings call for the period ending December 31, 2021.
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
01:13pm, Thursday, 03'rd Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Syros' Blood Cancer Drugs Land Orphan Designation From FDA
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)
Arrowhead down 4% after hours amid big earnings miss on both top and bottom lines
10:46pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Shares of Arrowhead Pharmaceuticals are down 4% in after-hours trading amid a significant miss on EPS in its FQ1 2022 results and a huge miss on revenue.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Dr. Christopher Anzalone on Q1 2022 Results - Earnings Call Transcript
09:40pm, Wednesday, 02'nd Feb 2022
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Dr. Christopher Anzalone on Q1 2022 Results - Earnings Call Transcript
Arrowhead Pharmaceuticals GAAP EPS of -$0.60 misses by $0.20, revenue of $27.4M misses by $23.64M (NASDAQ:ARWR)
09:10pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q1 GAAP EPS of -$0.60 misses by $0.20.Revenue of $27.4M (+28.6% Y/Y) misses by $23.64M.
